• Pharma
  • Pharma
  • Pharma
  • Pharma
  • Pharma

Pharma

cover

Retinal Diseases: Wet and Dry AMD, Diabetic Retinopathy Market 2016-2026

Aflibercept, Ranibizumab, Bevacizumab, Verteporfin, Ocriplasmin, Anti-VEGF, Anti-PDGF

This 208-page report provides quantitative and qualitative information on 10-years revenue forecasts to 2026 at overall world market, disease submarkets, product (brand) and national market level presented in 121 charts and discussion. The study gives revenue predictions to 2026 for four therapeutic submarkets at world level.

Product code
DPH0001
Publication date
12/07/2016
Number of Pages
208

 

 

  • A new report by DART Markets forecasts the overall world market for treating age-related macular degeneration (AMD or ARMD), diabetic retinopathy (DR) and other disorders of the retina will reach $17.38bn in 2020. That revenue forecast and others appear in Retinal Diseases: Wet and Dry AMD, Diabetic Retinopathy Market 2016-2026: Aflibercept, Ranibizumab, Bevacizumab, Verteporfin, Ocriplasmin, Anti-VEGF, Anti-PDGF, published in July 2016.

    This 208-page report provides quantitative and qualitative information on 10-years revenue forecasts to 2026 at overall world market, disease submarkets, product (brand) and national market level presented in 121 charts and discussion. The study gives revenue predictions to 2026 for four therapeutic submarkets at world level:

    • Wet age-related macular degeneration (wAMD)
    • Dry AMD (dAMD)
    • Diabetic retinopathy (DR)
    • Other retinal diseases (grouped forecast)

    Retinal Diseases: Wet and Dry AMD, Diabetic Retinopathy Market 2016-2026: Aflibercept, Ranibizumab, Bevacizumab, Verteporfin, Ocriplasmin, Anti-VEGF, Anti-PDGF

    Retinal Diseases: Wet and Dry AMD, Diabetic Retinopathy Market 2016-2026: Aflibercept, Ranibizumab, Bevacizumab, Verteporfin, Ocriplasmin, Anti-VEGF, Anti-PDGF


    The study also provides revenues and forecast of five prominent drugs to 2026:

    • Lucentis
    • Eylea
    • Avastin
    • Visudyne
    • Jetrea

    Retinal Diseases: Wet and Dry AMD, Diabetic Retinopathy Market 2016-2026: Aflibercept, Ranibizumab, Bevacizumab, Verteporfin, Ocriplasmin, Anti-VEGF, Anti-PDGF


    This report discusses the competitive landscape in the retinal diseases drugs market, which includes discussion on SWOT, STEP, Leading Companies, and M&A activities in this market.

    Research, data and analyses cover activities of leading companies in the retinal diseases drugs industry:

    • Roche
    • Novartis
    • Bayer
    • Allergan
    • Valeant
    • Other manufacturers and marketers of ophthalmic pharmaceuticals

    This new study also discusses leading pipeline candidates for Wet AMD, Dry AMD, and Diabetic Retinopathy, shows two interviews and predicts revenues to 2026 in 11 leading national markets. The work analyses these national markets:

    • US
    • Japan
    • EU5 (Italy, Spain, Germany, the UK and France)
    • BRIC (Brazil, Russia, India and China)
    • Rest of the World

    Retinal Diseases: Wet and Dry AMD, Diabetic Retinopathy Market 2016-2026: Aflibercept, Ranibizumab, Bevacizumab, Verteporfin, Ocriplasmin, Anti-VEGF, Anti-PDGF


    This report also provides a separate chapter on Pricing, Reimbursement, Market Access and Regulations, providing insights on these national markets:

    • US
    • Japan
    • EU5
    • Emerging Markets
  • CHAPTER 1: EXECUTIVE SUMMARY

    1.1 Report Description
    1.2 Questions Answered by This Report
    1.3 What This Report Provides
    1.4 Research Methodology

    CHAPTER 2: DISEASE AND MARKET OVERVIEW

    2.1 Epidemiology of Retinal Diseases?
    2.2 Diagnostics and Guidelines
    2.3 Retinal Diseases- Current Treatment Options

    CHAPTER 3: COMPETITIVE LANDSCAPE – RETINAL DISEASES DRUGS INDUSTRY

    3.1 STEP Analysis: Social, Technological, Economic and Political Factors Affecting the Retinal Diseases Industry and Market
    3.1.1 Social
    3.1.2 Technological
    3.1.3 Economic
    3.1.4 Political
    3.2 SWOT Analysis: Strengths, Weaknesses, Opportunities and Threats Affecting Retinal Diseases Market
    3.2.1 Strengths
    3.2.2 Weaknesses
    3.2.3 Opportunities
    3.2.4 Threats
    3.3 Leading Companies in Retinal Diseases Market
    3.3.1 Regeneron- Leading the Market with Eylea
    3.3.1.1 Regeneron- Revenue Performance Analysis, 2015
    3.3.1.2 Regeneron (Eylea) - Revenue Performance, 2015
    3.3.2 Novartis- Pushed Down to Second Position
    3.3.2.1 Novartis- Revenue Performance Analysis, 2015
    3.3.2.2 Novartis (Lucentis) - Revenue Performance, 2015
    3.3.3 Roche
    3.3.3.1 Roche - Revenue Performance Analysis, 2015
    3.3.3.2 Roche (Lucentis and Avastin) - Revenue Performance, 2015
    3.3.4 Bayer
    3.3.4.1 Bayer - Revenue Performance Analysis, 2015
    3.3.4.2 Bayer (Eylea) - Revenue Performance, 2015
    3.4 Mergers & Acquisitions in Retinal Diseases Drugs Industry, 2015

    CHAPTER 4: GLOBAL MARKET SEGMENTATION-WET AMD SUBMARKET

    4.1 Wet AMD Market, 2015
    4.2 Wet AMD Drugs: Market Forecast 2016-2026
    4.3 Porter’s Five Forces Analysis for Retinal Drug Industry
    4.4 Eylea: Leading Drug in the Market
    4.4.1 Revenue Continuosly Increasing in Past Years
    4.4.2 Is lucentis Inferior to Eylea?
    4.4.3 Has Eylea Already Achieved Maximum Profit Making Point?
    4.4.4 New Indications Approval for Eylea
    4.4.5 Eylea Revenue Forecast 2015-2026
    4.5 Lucentis: Reached Second Position in line
    4.5.1 Lucentis Acheieved Maximum Revenue in Past
    4.5.2 Avastin Hurdle for Lucentis Growth
    4.5.3 Lucentis Failed to Show Superiority to Avastin
    4.5.4 Lucentis Moves Into DME and Beyond
    4.5.5 Improving Cost and Compliance for Lucentis
    4.5.6 Lucentis Revenue Forecast 2015-2026
    4.5.7 Will Controversies Affect Lucentis’ Growth?
    4.6 Avastin: Leader in the Market by Volume
    4.6.1 Past Revenue in wet AMD: Increasing Use of Avastin
    4.6.2 Judicial Review for Price Adjustment
    4.6.3 Roche Effort’s to Block Off-Label Use of Avastin
    4.6.4 CATT study challenged by Roche and Novartis
    4.6.5 Will Avastin be affected by Eylea in the Market?
    4.6.6 Avastin Revenue Forecast, 2015-2026
    4.6.7 Avastin has Central Position in the Market
    4.7 Visudyne: Declining Sales Throughout
    4.7.1 Visudyne Revenue Forecast, 2015-2026
    4.8 Jetrea: Disappointing Launch in 2013
    4.8.1 Jetrea Revenue Forecast, 2015-2026

    CHAPTER 5: GLOBAL MARKET SEGMENTATION-DRY AMD SUBMARKET

    5.1 Dry AMD Market, 2015
    5.2 Dry AMD Drugs: Market Forecast 2016-2026

    CHAPTER 6: GLOBAL MARKET SEGMENTATION- DIABETIC RETINOPATHY SUBMARKET

    6.1 Diabetic Retinopathy Market, 2015
    6.2 Diabetic Retinopathy Drugs: Market Forecast 2016-2026

    CHAPTER 7: RETINAL DISEASES DRUGS: WORLD INDUSTRY

    7.1 Retinal Diseases Market Overview
    7.2 Retinal Diseases-Market Segmentation
    7.3 Retinal Diseases Market Forecast, 2016-2026
    7.4 Eylea Became the Leader in the Market
    7.5 Regeneron- Leading Company in the Market
    7.6 Significant Disease Areas for the Market
    7.7 Drivers and Restraints for Retinal Diseases Market

    CHAPTER 8: RETINAL DISEASES DRUGS INDUSTRY REVENUE, BY GEOGRAPHY

    8.1 National Market Overview: The US Dominates in 2015
    8.2 Regional Retinal Disease Market Forecast: 2016-2026
    8.3 The US: Leading Market for Retinal Diseases
    8.3.1 The US Market Forecast 2016-2026
    8.3.2 STEP Analysis for the US Market
    8.4 Japan: Strong Market Potential
    8.4.1 Japan Market Forecast 2016-2026
    8.4.2 STEP Analysis for Japan Market
    8.5 EU5: Ageing Populations to Drive Market Growth
    8.5.1 EU5 Market Forecast 2016-2026
    8.5.2 Germany Market Forecast 2016-2026
    8.5.3 France Market Forecast 2016-2026
    8.5.4 Italy Market Forecast 2016-2026
    8.5.5 UK Market Forecast 2016-2026
    8.5.6 Spain Market Forecast 2016-2026
    8.5.7 STEP Analysis for EU5 Market
    8.6 BRIC Nations: The Biggest Growth Driver for the Market
    8.6.1 BRIC Market Forecast 2016-2026
    8.6.2 China Market Forecast 2016-2026
    8.6.3 India Market Forecast 2016-2026
    8.6.4 Brazil Market Forecast 2016-2026
    8.6.5 Russia Market Forecast 2016-2026
    8.6.6 STEP Analysis for BRIC Market

    CHAPTER 9: RETINAL DISEASES R&D PIPELINE REVIEW

    9.1 The Leading Pipeline Candidates for Wet AMD
    9.2 Fovista (Ophthotech Corporation/Novartis): Waiting to Hit the Market
    9.2.1 Results for Three Phase 3 Trials to be Declared Soon
    9.2.2 New Move towards Combination Therapies
    9.2.3 Ophthotech Public Effort for Phase 3
    9.3 Conbercept (Chengdu Kanghong Biotech): Another Phase 3 Candidate
    9.4 Other Growth Factor Targets in the Pipeline
    9.4.1 Squalamine (OHR Pharmaceutical): Combination Targeting in a Single Eyedrop
    9.4.2 VEGF and PDGF Target for Allergan and Molecular Partners
    9.4.3 iSONEP (Lpath): Collaboration with Pfizer
    9.4.4 NT-506 (Neurotech Pharmaceutical): Sustained-Release VEGF/PDGF Options
    9.5 Is There a Need for New Anti-VEGFR Agents or Delivery Systems?
    9.5.1 Abicipar Pegol (Allergan): Novel Protein
    9.5.2 Brolucizumab (Alcon): Single- Chain Fv Fragment
    9.5.3 PDS 1.0 (ForSight Vision4): New Delivery System for Lucentis
    9.5.4 NT-503 (Neurotech): Improved Delivery Platform
    9.5.5 Pan-90806 (PanOptica): Anti-VEGF Eyedrop
    9.5.6 Iontophoretic Delivery: EyeGate Pharmaceuticals Leading the Way
    9.6 Novel Delivery Systems to Revitalize Anti-Inflammatory Approaches
    9.7 Other Targets in wet AMD Drug Development
    9.7.1 Kinase Inhibitors: Any success in wet AMD?
    9.7.2 Factor C5: A More Promising Target
    9.7.3 Integrins: Scope for Another VEGF Blockage Path?
    9.7.4 Jetrea (ThromboGenics/Novartis): Will it Help wet AMD Patients?
    9.7.5 Novel Treatments Targeting Angeogenisis
    9.8 Regenerative Medicine Approaches
    9.9 Pipeline for Dry AMD Segment, 2015-2026
    9.10 MC-1101 (MacuCLEAR): Leading the pipeline
    9.11 ACU-4429 (Acucela): Visual Cycle Modulator in Phase 3
    9.12 High Hopes for Complement Inhibition in Dry AMD
    9.12.1 Lampalizumab (Roche): Is it a major Breakthrough?
    9.13 Corticosteroids: Targeting Inflammation’s Role in Dry AMD Pathogenesis
    9.14 Neuroprotection: One of Modern Medicine’s Holy Grails
    9.14.1 Tandospirone (Alcon): Not effective in GA
    9.14.2 Renexsus (Neurotech): Hoping for Positive Results
    9.14.3 Novadur (Allergan): Longer Duration of Action
    9.14.4 VAR10200 (Varinel): A Preclinical Candidate to Watch
    9.15 Regenerative Medicine for Dry AMD Treatment
    9.15.1 Gene Therapies Less Prominent Than Stem Cells in Dry AMD
    9.15.2 OpRegen (Biotime): Leader in Stem Cells
    9.15.3 MA09-hRPE Cellular Therapy (Ocata Therapeutics)
    9.15.4 HuCNS-SC (StemCells): Leading Company in Neural Stem Cell Space
    9.15.5 Stemedyne-RPE (Stemedica Cell Technologies)
    9.15.6 First iPSC Trial in Japan in Dry AMD Patients
    9.16 Other Treatments for Dry AMD
    9.17 Pipeline for Diabetic Retinopathy Segment, 2015-2026
    9.17.1 Ozurdex/Posurdex (Allergan): Approved for General DME Patient Population
    9.17.2 Lucentis: The Game Changer for DR?
    9.17.3 New Anti-VEGF Additions
    9.18 Steroids in Development for DR
    9.19 Other Products in Development for DR
    9.19.1 Angiotensin Receptor Blockers/Angiotensin-Converting Enzyme Inhibitors: Some Off-Label Validation
    9.19.2 Vitreosolve (Innovations in Sight): Will a Phase 3 Trial Be Initiated?
    9.19.3 iCo-007 Intravitreal Injection (iCo Therapeutics): Phase 2 Enrolment Completed June 2013
    9.19.4 Jetrea (ThromboGenics/Novartis): Possibilities in DME?

    CHAPTER 10: PRICING, REIMBURSEMENT AND MARKET ACCESS

    10.1 Regulatory Hurdles and Update on Regulations – Retinal Diseases Drugs Market
    10.1.1 US
    10.1.2 Japan
    10.1.3 EU5
    10.1.4 Emerging Markets
    10.2 Pricing, Reimbursement and Market Access – Retinal Diseases Drugs Market
    10.2.1 US
    10.2.2 Japan
    10.2.3 EU5
    10.2.4 Emerging Markets

    CHAPTER 11: EXPERT OPINIONS

    11.1 Interview with Ms. Cathy Yelf, CEO, Macular Society, UK
    11.2 Interview with Dr. Ken Green, Senior Vice President and Chief Scientific Officer, Alimera Sciences, Inc.

    CHAPTER 12: RETINAL DISEASES DRUGS MARKET CONCLUSIONS AND RECOMMENDATIONS FOR BUSINESS STRATEGIES

    12.1 Eylea Taken Over Lucentis Market
    12.2 Three Competitors for Anti-VEGF Market
    12.3 Wet AMD Drugs Expanding to Other Indications
    12.4 Extensive Opportunities in Dry AMD Market
    12.5 Fovista To Launch Soon With High Expectations
    12.6 Retinal Diseases Holds the Largest Area of Ophthalmics
    12.7 Recommendation: Opportunities Available in the Market

    APPENDIX

    DART Report Evaluation Form

    LIST OF FIGURES

    Figure 1: AMD and Other Retinal Diseases Drug Market Share (%), 2015
    Figure 2: STEP Analysis for Retinal Diseases Market, 2016-2026
    Figure 3: SWOT analysis of Retinal Diseases Market, 2016-2026
    Figure 4: Regeneron Historical Revenue ($bn), 2011-2015
    Figure 5: Novartis Historical Revenue ($bn), 2011-2015
    Figure 6: Novartis Revenue Share (%) by Segment, 2015
    Figure 7: Roche Historical Revenue ($bn), 2011-2015
    Figure 8: Roche Revenue Share (%) by Segment, 2015
    Figure 9: Bayer’s Pharmaceutical Segment Historical Revenue ($bn), 2011-2015
    Figure 10: Market Breakdown by Product Market Share (%), 2020
    Figure 11: Market Breakdown by Product: Market Share (%), 2026
    Figure 12: Market Forecast by Product: Revenue ($bn), 2015-2026
    Figure 13: Market Breakdown by Product: Revenue ($bn), 2015, 2020 and 2026
    Figure 14: Wet AMD Segment Forecast Revenue ($bn), 2015-2026
    Figure 15: Porter’s Five Forces Analysis for Drugs, 2015
    Figure 16: Eylea Forecast Revenue ($bn), 2015-2026
    Figure 17: Lucentis Forecast Revenue ($bn), 2015-2026
    Figure 18: Avastin Forecast Revenue ($bn), 2015-2026
    Figure 19: Visudyne Forecast Revenue ($bn), 2015-2026
    Figure 20: Jetrea Forecast Revenue ($bn), 2015-2026
    Figure 21: Dry AMD Segment Forecast Revenue ($bn), 2015-2026
    Figure 22: DR Segment Forecast Revenue ($bn), 2015-2026
    Figure 23: World AMD and Other Retinal Diseases Market Forecast Revenue ($bn), 2015-2026
    Figure 24: Market Breakdown by Disease Segment Revenues ($bn), 2015
    Figure 25: Market Breakdown by Disease Segment Market Share (%), 2015
    Figure 26: Retinal Diseases Market Breakdown by Segment Revenue ($bn), 2015, 2020 and 2026
    Figure 27: Retinal Diseases Market Breakdown by Segment Revenue ($bn), 2015-2026
    Figure 28: Market Breakdown by Disease Segment Market Share (%), 2020
    Figure 29: Market Breakdown by Disease Segment Market Share (%), 2026
    Figure 30: Market Breakdown by Products Revenue ($bn), Market Share (%), 2015
    Figure 31: Market Breakdown by Company Market Share (%), 2015
    Figure 32: Leading Causes of Blindness Worldwide, Proportion of Total (%), 2010
    Figure 33: Leading Causes of Visual Impairment (Inclusive of Blindness) Worldwide, Proportion of Total (%), 2010
    Figure 34: The National Market Share (%) of Retinal Diseases, 2015
    Figure 35: Regional Market Breakdown Revenue ($bn), 2015, 2020 and 2026
    Figure 36: The National Market Share (%) of Retinal Diseases, 2020
    Figure 37: The National Market Share (%) of Retinal Diseases, 2026
    Figure 38: US Retinal Diseases Market Forecast Revenue ($bn), 2015-2026
    Figure 39: STEP Analysis for Retinal Diseases Market in the US, 2016-2026
    Figure 40: Japan Retinal Diseases Market Forecast Revenue ($bn), 2015-2026
    Figure 41: STEP Analysis for Retinal Diseases Market in Japan, 2016-2026
    Figure 42: EU5 Retinal Diseases Market Share (%) Forecast, 2015, 2020 and 2026
    Figure 43: EU5 Retinal Diseases Market Forecast Revenue ($bn), 2015-2026
    Figure 44: Germany Retinal Diseases Market Revenue ($bn) Forecast, 2015-2026
    Figure 45: France Retinal Diseases Market Revenue ($bn) Forecast, 2015-2026
    Figure 46: Italy Retinal Diseases Market Revenue ($bn) Forecast, 2015-2026
    Figure 47: UK Retinal Diseases Market Revenue ($bn) Forecast, 2015-2026
    Figure 48: Spain Retinal Diseases Market Revenue ($bn) Forecast, 2015-2026
    Figure 49: STEP Analysis for Retinal Diseases Market in EU5, 2016-2026
    Figure 50: BRIC Retinal Diseases Market Revenue ($bn) Forecast, 2015-2026
    Figure 51: BRIC Retinal Diseases Market Share (%) Forecast, 2015, 2020 and 2026
    Figure 52: China Retinal Diseases Market Revenue ($bn) Forecast, 2015-2026
    Figure 53: India Retinal Diseases Market Revenue ($bn) Forecast, 2015-2026
    Figure 54: Brazil Retinal Diseases Market Revenue ($bn) Forecast, 2015-2026
    Figure 55: Russia Retinal Diseases Market Revenue ($bn) Forecast, 2015-2026
    Figure 56: STEP Analysis for Retinal Diseases Market in BRIC, 2016-2026
    Figure 57: Healthcare Expenditure and GDP For Countries, 2013
    Figure 58: National Market CAGR (%), 2015-2026
    Figure 59: Retinal Diseases Drugs Revenue ($bn), 2015
    Figure 60: Retinal Market Segments CAGR (%), 2015-2026

    LIST OF TABLES

    Table 1: World AMD and Other Retinal Diseases Market Revenue ($bn) Forecast, 2015-2026
    Table 2: Bayer Pharmaceutical Segment Revenue ($bn) by Region, 2014 and 2015
    Table 3: Types of CNV in Wet AMD: Approximate Proportion of Cases (%), 2014
    Table 4: Retinal Diseases Drug Revenue Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026
    Table 5: Market Breakdown by Product: Revenue ($bn), Market Share (%), 2020
    Table 6: Market Breakdown by Product: Revenue ($bn), Market Share (%), 2026
    Table 7: Wet AMD Segment Forecast Revenue ($bn), AGR (%), CAGR (%), 2015-2020
    Table 8: Wet AMD Segment Forecast Revenue ($bn), AGR (%), CAGR (%), 2020-2026
    Table 9: Eylea Historical Revenue ($bn), AGR (%), 2012-2015
    Table 10: Eylea Forecast Revenue ($bn), AGR (%), CAGR (%), 2015-2020
    Table 11: Eylea Forecast Revenue ($bn), AGR (%), CAGR (%), 2020-2026
    Table 12: Lucentis Historical Revenue ($bn), AGR (%), 2011-2015
    Table 13: Lucentis, Eylea and Avastin Comparison of Reported Characteristics
    Table 14: Lucentis Forecast Revenue ($bn), AGR (%), CAGR (%), 2015-2020
    Table 15: Lucentis Forecast Revenue ($bn), AGR (%), CAGR (%), 2020-2026
    Table 16: Avastin Historical Revenue ($bn), AGR (%), 2011-2015
    Table 17: Avastin Forecast Revenue ($bn), AGR (%), CAGR (%), 2015-2020
    Table 18: Avastin Forecast Revenue ($bn), AGR (%), CAGR (%), 2020-2026
    Table 19: Visudyne Forecast Revenue ($bn), AGR (%), CAGR (%), 2015-2020
    Table 20: Visudyne Forecast Revenue ($bn), AGR (%), CAGR (%), 2020-2026
    Table 21: Jetrea Forecast Revenue ($bn), AGR (%), CAGR (%), 2015-2020
    Table 22: Jetrea Forecast Revenue ($bn), AGR (%), CAGR (%), 2020-2026
    Table 23: Dry AMD Segment Revenue ($bn), AGR (%), CAGR (%), 2015-2020
    Table 24: Dry AMD Segment Revenue ($bn), AGR (%), CAGR (%), 2020-2026
    Table 25: DR Segment Revenue ($bn), AGR (%), CAGR (%), 2015-2020
    Table 26: DR Segment Revenue ($bn), AGR (%), CAGR (%), 2020-2026
    Table 27: World AMD and Other Retinal Diseases Market Forecast Revenue ($bn), AGR (%), CAGR (%), 2015-2020
    Table 28: World AMD and Other Retinal Diseases Market Forecast Revenue ($bn), AGR (%), CAGR (%), 2020-2026
    Table 29: Market Breakdown by Disease Segment Revenue ($bn), Market Share (%), 2015
    Table 30: Retinal Diseases Market Forecasts by Segment Revenue ($bn), Market Share (%) for 2015, 2020 and 2026
    Table 31: Retinal Diseases Market Forecasts by Segment Revenues ($bn), AGR (%), CAGR (%), 2015-2026
    Table 32: Market Breakdown by Products Market Share (%), 2015
    Table 33: The National Market Breakdown by Revenue ($bn) and Market Share (%), 2015
    Table 34: Regional Market Breakdown Forecast Revenue ($bn), AGR (%), CAGR (%), 2015-2026
    Table 35: US Retinal Diseases Market Forecast Revenue ($bn), AGR (%), CAGR (%), 2015-2020
    Table 36: US Retinal Diseases Market Forecast Revenue ($bn), AGR (%), CAGR (%), 2020-2026
    Table 37: Japan Retinal Diseases Market Forecast Revenue ($bn), AGR (%), CAGR (%), 2015-2020
    Table 38: Japan Retinal Diseases Market Forecast Revenue ($bn), AGR (%), CAGR (%), 2020-2026
    Table 39: EU5 Retinal Diseases Market Forecast Revenue ($bn), AGR (%) and CAGR (%), 2015-2026
    Table 40: Germany Retinal Diseases Market Forecast Revenue ($bn), AGR (%), CAGR (%), 2015-2020
    Table 41: Germany Retinal Diseases Market Forecast Revenue ($bn), AGR (%), CAGR (%), 2020-2026
    Table 42: France Retinal Diseases Market Forecast Revenue ($bn), AGR (%), CAGR (%), 2015-2020
    Table 43: France Retinal Diseases Market Forecast Revenue ($bn), AGR (%), CAGR (%), 2020-2026
    Table 44: Italy Retinal Diseases Market Forecast Revenue ($bn), AGR (%), CAGR (%), 2015-2020
    Table 45: Italy Retinal Diseases Market Forecast Revenue ($bn), AGR (%), CAGR (%), 2020-2026
    Table 46: UK Retinal Diseases Market Forecast Revenue ($bn), AGR (%), CAGR (%), 2015-2020
    Table 47: UK Retinal Diseases Market Forecast Revenue ($bn), AGR (%), CAGR (%), 2020-2026
    Table 48: Spain Retinal Diseases Market Forecast Revenue ($bn), AGR (%), CAGR (%), 2015-2020
    Table 49: Spain Retinal Diseases Market Forecast Revenue ($bn), AGR (%), CAGR (%), 2020-2026
    Table 50: BRIC Retinal Diseases Market Forecast Revenue ($bn), AGR (%) and CAGR (%), 2015-2026
    Table 51: China Retinal Diseases Market Forecast Revenue ($bn), AGR (%) and CAGR (%), 2015-2020
    Table 52: China Retinal Diseases Market Forecast Revenue ($bn), AGR (%) and CAGR (%), 2020-2026
    Table 53: India Retinal Diseases Market Forecast Revenue ($bn), AGR (%) and CAGR (%), 2015-2020
    Table 54: India Retinal Diseases Market Forecast Revenue ($bn), AGR (%) and CAGR (%), 2020-2026
    Table 55: Brazil Retinal Diseases Market Forecast Revenue ($bn), AGR (%) and CAGR (%), 2015-2020
    Table 56: Brazil Retinal Diseases Market Forecast Revenue ($bn), AGR (%) and CAGR (%), 2020-2026
    Table 57: Russia Retinal Diseases Market Forecast Revenue ($bn), AGR (%) and CAGR (%), 2015-2020
    Table 58: Russia Retinal Diseases Market Forecast Revenue ($bn), AGR (%) and CAGR (%), 2020-2026
    Table 59: Selected R&D Wet AMD Pipeline, 2015
    Table 60: Selected R&D Dry AMD Pipeline, 2015
    Table 61: Selected R&D Diabetic Retinopathy Pipeline, 2015
  • Abbott
    Acucela
    Alcon
    Aldexa
    Alimera Sciences
    Alkeus Pharmaceuticals
    Allegro
    Allergan
    Allergan and Molecular Partners
    Ampio Pharmaceuticals
    Association for Research in Vision and Ophthalmology
    Avalanche Biotechnologies
    Bayer Healthcare
    Biotime
    Biovail Corporation
    Bristol-Myers Squibb
    Casey Eye Institute
    Chengdu Kanghong Biotech
    Colby Pharmaceutical
    Columbia University
    CoMentis
    Eli Lilly
    EyeGate Pharmaceuticals
    Eyetech
    FDA
    ForSight Vision4
    Genentech
    Germany’s Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)
    GlaxoSmithKline (GSK)
    iCo Therapeutics
    Icon Bioscience
    International Diabetes Federation
    Italian Competition Authority (ICA)
    Japanese Ministry of Health, Labour and Welfare
    Lpath, Inc.
    MacuCLEAR
    Mesoblast
    MSD
    Neuron Systems Inc.
    Neurotech
    NHS
    NICE
    Novartis
    Novo Nordisk
    Ocata Therapeutics
    OHR Pharmaceutical
    Ophthotec Corporation
    Ora Bio
    Oregon Health and Science University
    Othera Pharmaceuticals
    Oxford BioMedica
    Oxigene
    PanOptica
    Pfizer
    QLT
    Regeneron
    ReVision Therapeutics
    Roche
    Santen Pharmaceutical
    Sirion Therapeutics
    StemCells
    Stemedica Cell Technologies
    ThromboGenics
    Tyrogenex
    UCB
    UK’s General Medical Council
    University College London (UCL)
    US National Eye Institute
    Valeant Pharmaceuticals
    Varinel
    VisionCare Ophthalmic Technologies
    Vitreoretinal Technologies
    WHO
    Xcovery Group
    Xcovery Vision
  • Single User Licence
    £3800
    Departmental Licence
    £4900
    Site Licence
    £5999
    Global Licence
    £7999

    Single User License: This license allows for use of a report by one named person, explicitly confirmed at point of sale. This person may use the report but may not share the report (or any information contained therein) with any other person or persons. Unless a Departmental License, a Site License or a Global Site License is purchased, a Single User License must be purchased for every person that wishes to use the report within the same enterprise. The license is valid for 12 months from the date the report is sent.

    Departmental Licenses: This license allows for use of a report by six people within the same enterprise location. You may print a copy of the report under each user. Each of these people may use the report but may not share the report (or any information contained therein) with any other person or persons. DART provides a service whereby we print, bind and ship a hard copy report for you, in full colour. But this service is only available for clients who purchase a departmental licence or above. The license is valid for 12 months from the date the report is sent.

    Site License: This license allows for use of a report by an unlimited number of people within the same enterprise location. Each of these people may use the report on any computer, and may print out the report, but may not share the report (or any information contained therein) with any person or persons outside of the enterprise location. There is no time limit access to the report.

    Global License: This license allows for use of a report by an unlimited number of people within the same enterprise worldwide. Each of these people may use the report on any computer, and may print out the report, but may not share the report (or any information contained therein) with any other person or persons outside of the enterprise. Datasets refers to the Excel spread sheets that we have formulated and which details the global, regional/national and submarket data as shown within our reports. There is no time limit access to the report.

Copyright © DART Markets. All rights reserved.

Cookie policy

We use cookies on our website. By using our website you agree to this Policy and you consent to our use of cookies in accordance with the terms of this Policy.

About Cookies
A cookie is a small file which asks permission to be placed on your computer's hard drive. Once you agree, the file is added and the cookie helps analyse web traffic or lets you know when you visit a particular site. Cookies allow web applications to respond to you as an individual. The web application can tailor its operations to your needs, likes and dislikes by gathering and remembering information about your preferences.

There are two main kinds of cookies: "session" cookies and "persistent" cookies. Session cookies only last for the duration of users using the website and are deleted from your computer when you close your browser, whereas persistent cookies outlast user sessions and remain stored on your computer until deleted, or until they reach their expiry date.

Cookies help us provide you with a better website, by enabling us to monitor which pages you find useful and which you do not.

Cookies do not contain any information that personally identifies you, a cookie in no way gives us access to your computer or any information about you.

You can choose to accept or decline cookies. Most web browsers automatically accept cookies, but you can usually modify your browser setting to decline cookies if you prefer. This may prevent you from taking full advantage of the website.

Cookies on this Website
We use persistent cookies on this website to provide links to social network sharing services, and to update you on our most popular content.

Third Party Cookies
We do not use third party cookies.

Google Analytics
We also use cookies to help us improve the website's usability and for marketing purposes. We may also use cookies to identify which pages are being used. This helps us analyse data about webpage traffic and improve our website in order to tailor it to customer needs. We only use this information for statistical analysis purposes and then the data is removed from the system.

For this purpose we use Google Analytics. Google Analytics generates statistical and other information about website use by means of cookies, which are stored on users' computers. The information generated relating to our website is used to create reports about the use of the website. Google will store and use this information. Google's privacy policy is available at www.google.com/privacypolicy.html.

This website cookies policy template is based on a free document supplied by The Legal Stop Limited through its website www.thelegalstop.co.uk.

If you have any questions about privacy please contact us.